Tata Motors: Tata Motors stock rises 1% on strong JLR sales, bullish brokerages.
The Tata motors sales of Jaguar Landrover rose to 11% in Q4 and sales of 114038 units done in Q4. Retail Sales in UK grew upto 32% and 21% in North America and 16% in other international countries. Expected level of sales achieved in Q4 makes Tata Motors shares up today.
TATA MOTORS Market Price is moving in uptrend line and market has rebounded from the higher low area of the pattern
Tata Motors Limited saw its shares rise by 1.3 percent to Rs 1,026 on April 9, continuing its upward trajectory, following the news of robust performance from its British luxury subsidiary, Jaguar Land Rover (JLR). JLR reported a notable 11 percent year-on-year growth in retail sales for the fourth quarter, reaching 114,038 units, surpassing market expectations. However, analysts expressed caution regarding margins due to the product mix.
The increase in JLR sales is attributed to heightened production levels and sustained global demand. Notably, retail sales saw significant growth rates of 32 percent in the UK, 21 percent in North America, and 16 percent internationally compared to the previous year. Despite this positive trend, sales in China, one of JLR’s major markets, declined by 9 percent, and Europe saw a 2 percent decrease, as reported in a business update.
For the March quarter, wholesale volumes reached 110,190 vehicles, marking a 16 percent increase from the same period last year.
NATCO: Lupin, Glenmark, Natco recall US market products.
The NATCO, Glenmark and Lupin Pharma companies recalled 30 bottles of Gastritis, 6528 bottles of High Blood pressure,26352 bottles of Tuberclosis from the US after the Class 2 US FDA Observations done in this companies.
NATCO PHARMA Market Price is moving in Ascending channel and market has fallen from the higher high area of the channel
According to the latest Enforcement Report by the US Food and Drug Administration (FDA), homegrown pharmaceutical giants Lupin Ltd, Glenmark Pharmaceuticals Ltd, and Natco Pharma Ltd have initiated recalls of several products from the US markets.
Lupin is recalling 26,352 bottles of Rifampin capsules, which are utilized in the treatment of all forms of tuberculosis, in the US market due to identification as a sub-potent drug. These capsules were manufactured in Lupin’s Aurangabad plant in India and distributed by Lupin’s US arm. The recall process commenced on March 21 and has been classified as a Class II recall by the US FDA.
Similarly, Glenmark Pharmaceuticals has recalled 6,528 bottles of Diltiazem Hydrochloride capsules, prescribed for high blood pressure treatment, from the US market. The product failed dissolution specifications, as per the US FDA. These capsules were manufactured in India and distributed by Glenmark’s US arm. The recall, categorized as a Class II recall, was initiated on March 26.
Natco Pharma also joined the recall efforts by recalling 30 bottles of Lansoprazole capsules, used in treating gastritis, from the US market. Manufactured in Natco’s plant in Kothur, India, these capsules were found to have deviations from Current Good Manufacturing Practice (CGMP). The recall was initiated on March 27 and has been classified as a Class II recall by the US FDA.
According to the US Food and Drug Administration (FDA), a Class II recall pertains to situations where the use of, or exposure to, the product may lead to temporary or medically reversible adverse health consequences. Alternatively, in cases where the probability of serious adverse health consequences is deemed remote, a Class II recall may also be issued.
Moreover, data from the Indian Pharmaceutical Association indicates the significant role played by Indian companies in global pharmaceutical supply. Indian pharmaceutical firms supply 20 percent of the world’s pharmaceutical generics, highlighting their substantial presence in the global market. Additionally, they contribute to 60 percent of global vaccines and 40 percent of medicines supplied to the US, underlining their extensive contribution to healthcare worldwide.
The Dilip Buildcon Project company has get the Order of Rs.1092.46 cr from Haryana Rail corporation for building 21.14 km Electrical services project. Already from Goa Government , project worth Rs. 270.07 cr has bagged last month.
DILIP BUILDCON Market Price is moving in Ascending channel and market has reached higher high area of the channel
In early trading hours, the share price of Dilip Buildcon surged by 3 percent following the announcement that the company had emerged as the lowest bidder for a project awarded by the Haryana Rail Infrastructure Development Corporation.
The contract secured by Dilip Buildcon entails the construction of a new BG Double Railway Line for the HORC project between Prithla and Dhulawat stations. The scope of work involves design, supply, installation, testing, and commissioning of general electrical services, covering a total length of 21.14 kilometers under the Engineering, Procurement, and Construction (EPC) mode.
In other developments, in February, Dilip Buildcon inked a concession agreement with the Public Works Department in Goa for the construction of observatory towers, viewing galleries, approaches, decorative lighting, and parking for the New Zuari Bridge on the Panjim-Mangalore section in Goa. The project’s total cost stands at Rs 270.07 crore.
Don’t trade all the time, trade forex only at the confirmed trade setups
Get more confirmed trade signals at premium or supreme – Click here to get more signals , 2200%, 800% growth in Real Live USD trading account of our users – click here to see , or If you want to get FREE Trial signals, You can Join FREE Signals Now!
